| Literature DB >> 33498716 |
Diane Ashiru-Oredope1, Frances Kerr2, Stephen Hughes1, Jonathan Urch1, Marisa Lanzman1, Ting Yau1, Alison Cockburn2, Rakhee Patel1, Adel Sheikh1, Cairine Gormley3, Aneeka Chavda1, Tejal Vaghela1, Ceri Phillips4, Nicholas Reid4, Aaron Brady3.
Abstract
Since first identified in late 2019, the acute respiratory syndrome coronavirus (SARS-CoV2) and the resulting coronavirus disease (COVID-19) pandemic has overwhelmed healthcare systems worldwide, often diverting key resources in a bid to meet unprecedented challenges. To measure its impact on national antimicrobial stewardship (AMS) activities, a questionnaire was designed and disseminated to antimicrobialstewardship leads in the United Kingdom (UK). Most respondents reported a reduction in AMS activity with 64% (61/95) reporting that COVID-19 had a negative impact on routine AMS activities. Activities reported to have been negatively affected by the pandemic include audit, quality improvement initiatives, education, AMS meetings, and multidisciplinary working including ward rounds. However, positive outcomes were also identified, with technology being increasingly used as a tool to facilitate stewardship e.g., virtual meetings and ward rounds and increased the acceptance of using procalcitonin tests to distinguish between viral and bacterial infections. The COVID-19 pandemic has had a significant impact on the AMS activities undertaken across the UK. The long-term impact of the reduced AMS activities on incidence of AMR are not yet known. The legacy of innovation, use of technology, and increased collaboration from the pandemic could strengthen AMS in the post-pandemic era and presents opportunities for further development of AMS.Entities:
Keywords: AMR; AMS; COVID-19; SARS-CoV-2; antimicrobial resistance; antimicrobial stewardship; coronavirus
Year: 2021 PMID: 33498716 PMCID: PMC7912640 DOI: 10.3390/antibiotics10020110
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382